REFERENCES

to be free of widespread intravascular fibrin deposition and had no signs of a consumption coagulopathy, whereas nonchallenged mice had normal bleeding times. In these elegant proof-of-principle experiments it is demon-strated that targeted delivery of anticoagulant agents at the surface of activated cells (ie, at the site of coagulation activation) may be a worth-while approach to pursue. Additional bone marrow reconstitution experiments in this article show that endothelial cells in particular may be the pivotal target for this local treatment. A detailed analysis of the function of co-agulation in vivo has in recent years led to the development of new, potent, and highly spe-cific antithrombotic agents. The experiments of Chen et al indicate that targeting the cell surface may well be the next step in further improving anticoagulant treatment